# VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia

> **NCT00505700** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** velcade
- **DRUG:** Idarubicin
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT00505700
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2005-09
- **Final completion:** —
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2010-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00505700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00505700, "VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00505700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*